Form 4: Cyclo Therapeutics Director Markus Sieger Receives Stock and Options as Compensation

Director Markus Sieger received shares and options from Cyclo Therapeutics as part of his compensation, according to a recent SEC filing.

Summary

• Markus Sieger, a director at Cyclo Therapeutics, received 18,067 shares of common stock on June 3, 2024, as compensation for the first quarter of 2024.
• These shares were granted in lieu of cash compensation under the company's non-employee director compensation policy.
• The shares were valued at $1.28 each, based on the closing price on June 3, 2024.
• Sieger also received options to purchase 15,562 shares of common stock at an exercise price of $1.28.
• The options vest over a one-year period in equal quarterly installments and expire on June 3, 2034.
• Following these transactions, Sieger directly owns 328,746 shares of Cyclo Therapeutics.

Sentiment

Score: 7

Explanation: The document reflects standard compensation practices, which is generally viewed neutrally to positively as it aligns director interests with shareholders.

Positives

• The grant of shares and options to a director aligns their interests with those of the shareholders.
• The vesting schedule of the options incentivizes the director to remain with the company.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This type of equity compensation is common for directors of publicly traded companies, aligning their interests with shareholders and incentivizing performance.

Comparison to Industry Standards

• Equity compensation for board members is a standard practice across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen often use a mix of cash and equity to compensate their directors.
• The specific amount and type of equity granted can vary based on company size, performance, and individual contributions.

Stakeholder Impact

• Shareholders may view the equity compensation positively as it aligns the director's interests with the company's performance.
• Employees may see this as a standard practice for director compensation.

Key Dates